Your browser doesn't support javascript.
loading
Health impact and cost-effectiveness of expanding routine immunization coverage in India through Intensified Mission Indradhanush.
Clarke-Deelder, Emma; Suharlim, Christian; Chatterjee, Susmita; Portnoy, Allison; Brenzel, Logan; Ray, Arindam; Cohen, Jessica L; Menzies, Nicolas A; Resch, Stephen C.
Affiliation
  • Clarke-Deelder E; Department of Global Health and Population, Harvard T. H. Chan School of Public Health, Boston, MA 02115, United States.
  • Suharlim C; Department of Epidemiology and Public Health, Swiss Tropical & Public Health Institute, Allschwil 4123, Switzerland.
  • Chatterjee S; University of Basel, Basel 4001, Switzerland.
  • Portnoy A; Center for Health Decision Science, Harvard T. H. Chan School of Public Health, Boston, MA 02115, United States.
  • Brenzel L; Management Sciences for Health, Medford, MA 02155, United States.
  • Ray A; Research Department, George Institute for Global Health, New Delhi, Delhi 110025, India.
  • Cohen JL; Department of Medicine, University of New South Wales, New South Wales 2052, Australia.
  • Menzies NA; Center for Health Decision Science, Harvard T. H. Chan School of Public Health, Boston, MA 02115, United States.
  • Resch SC; Department of Global Health, Boston University School of Public Health, Boston, MA 02118, United States.
Health Policy Plan ; 39(6): 583-592, 2024 Jun 03.
Article in En | MEDLINE | ID: mdl-38590052
ABSTRACT
Many children do not receive a full schedule of childhood vaccines, yet there is limited evidence on the cost-effectiveness of strategies for improving vaccination coverage. Evidence is even scarcer on the cost-effectiveness of strategies for reaching 'zero-dose children', who have not received any routine vaccines. We evaluated the cost-effectiveness of periodic intensification of routine immunization (PIRI), a widely applied strategy for increasing vaccination coverage. We focused on Intensified Mission Indradhanush (IMI), a large-scale PIRI intervention implemented in India in 2017-2018. In 40 sampled districts, we measured the incremental economic cost of IMI using primary data, and used controlled interrupted time-series regression to estimate the incremental vaccination doses delivered. We estimated deaths and disability-adjusted life years (DALYs) averted using the Lives Saved Tool and reported cost-effectiveness from immunization programme and societal perspectives. We found that, in sampled districts, IMI had an estimated incremental cost of 2021US$13.7 (95% uncertainty interval 10.6 to 17.4) million from an immunization programme perspective and increased vaccine delivery by an estimated 2.2 (-0.5 to 4.8) million doses over a 12-month period, averting an estimated 1413 (-350 to 3129) deaths. The incremental cost from a programme perspective was $6.21 per dose ($2.80 to dominated), $82.99 per zero-dose child reached ($39.85 to dominated), $327.63 ($147.65 to dominated) per DALY averted, $360.72 ($162.56 to dominated) per life-year saved and $9701.35 ($4372.01 to dominated) per under-5 death averted. At a cost-effectiveness threshold of 1× per-capita GDP per DALY averted, IMI was estimated to be cost-effective with 90% probability. This evidence suggests IMI was both impactful and cost-effective for improving vaccination coverage, though there is a high degree of uncertainty in the results. As vaccination programmes expand coverage, unit costs may increase due to the higher costs of reaching currently unvaccinated children.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Cost-Benefit Analysis / Immunization Programs / Vaccination Coverage Limits: Child, preschool / Humans / Infant Country/Region as subject: Asia Language: En Year: 2024 Type: Article

Full text: 1 Database: MEDLINE Main subject: Cost-Benefit Analysis / Immunization Programs / Vaccination Coverage Limits: Child, preschool / Humans / Infant Country/Region as subject: Asia Language: En Year: 2024 Type: Article